For Immediate Release
Chicago, IL – July 18, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AstraZeneca (AZN - Analyst Report), The Medicines Company (MDCO - Analyst Report), Bristol-Myers Squibb & Co. (BMY - Analyst Report), Sanofi (SNY - Analyst Report) and Eli Lily (LLY - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Good News for AstraZeneca
Good news flowed in at AstraZeneca (AZN - Analyst Report) with the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) panel of experts updating their guidelines and issuing a class 1 recommendation for Brilinta (ticagrelor). The class 1 recommendation was issued for the use of Brilinta in invasively and non-invasively managed patients suffering from unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI).
We note that anti-platelet Brilinta has received the highest recommendation issued by the guidelines committee. We believe that this will encourage physicians to prescribe Brilinta and provide a much needed boost to Brilinta sales.
Brilinta is approved for reducing the rate of heart attack and cardiovascular (CV) events in adult patients with acute coronary syndrome (ACS) including UA, NSTEMI and ST-elevation myocardial infarction (STEMI).
Brilinta was approved in the US in July 2011. However, Brilinta’s sales have been lackluster so far. Brilinta sales amounted to $9 million in the first quarter of 2012 compared with $5 million in the fourth quarter of 2011. In April 2012, AstraZeneca collaborated with The Medicines Company (MDCO - Analyst Report) to market Brilinta in the US. The Medicines Company’s strong presence in the hospital setting should help drive Brilinta sales.
Brilinta competes with other drugs in the anti-platelet market including Bristol-Myers Squibb & Co. (BMY - Analyst Report) and Sanofi’s (SNY - Analyst Report) Plavix (clopidogrel) and Eli Lily’s (LLY - Analyst Report) Effient (prasugrel).
Neutral on AstraZeneca
We are encouraged by AstraZeneca’s focus on high-potential emerging markets and are pleased with its effort to drive the bottom line through cost-cutting initiatives and share buybacks.
However, we remain concerned about the generic competition faced by the company’s key products. In 2011, the company lost revenues worth almost $2 billion to generic competition. The weak late-stage pipeline coupled with slow Brilinta uptake also bothers us.
We currently have a Neutral recommendation on AstraZeneca. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339